# Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations

> **NCT03794297** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Erdheim-Chester Disease

## Interventions

- **DRUG:** Dabrafenib Mesylate
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration
- **DRUG:** Trametinib Dimethyl Sulfoxide

## Key facts

- **NCT ID:** NCT03794297
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-01-04
- **Primary completion:** 2021-02-18
- **Final completion:** 2021-02-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate accrual rate
- **Last updated:** 2021-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03794297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03794297, "Dabrafenib and Trametinib in Treating Patients With Erdheim Chester Disease With BRAF V600 Mutations". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03794297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*